Valuation
- Market cap
- 519,996,000
- Revenue TTM
- $890,000
- Net income TTM
- $-68,990,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -7,751.69%
- Debt to equity
- 0.00
Trading
- Volume
- 1,089,600
- Avg volume
- 1,366,544
- Day's range
- $1.66 – $1.75
- Shares out
- 302,323,000
- Stochastic %K
- 56%
- Beta
- 1.77
- Analysts
- Sell
- Price target
- $5.50
Company profile
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserv...
Show more
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 336 999 7019
- Website
- https://prokidney.com
- Address
- 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, United States
Latest news
No headlines yet.
